STAT3 is one of the GBM therapeutic targets, whilst Exo-An2-siRNA is taken up by GBM cells and releases siRNA to silence STAT3, significantly inhibiting downstream target oncogene transcription, and ultimately leading to significant apoptosis in GBM cells. The gene discussed is STAT3; the disease is glioblastoma.